The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase II study of suberoylanilide hydroxamic acid (SAHA) in subjects with locally advanced, recurrent, or metastatic adenoid cystic carcinoma (ACC).
Priscila Hermont Goncalves
No relevant relationships to disclose
Shivaani Kummar
No relevant relationships to disclose
Lillian L. Siu
Employment or Leadership Position - Agios (I); Bayer (Other); Boehringer Ingelheim; Bristol-Myers Squibb; Celgene (Other); EntreMed (I); GlaxoSmithKline (Other); Merck (Other); Novartis (Other); Pfizer Inc. (Other); Regeneron (Other)
Consultant or Advisory Role - Boehringer Ingelheim; Oncoethix
Stock Ownership - Agios (I); EntreMed (I); Rigel Pharmaceuticals Inc. (I)
Aaron Richard Hansen
No relevant relationships to disclose
Panayiotis Savvides
No relevant relationships to disclose
Ammar Sukari
No relevant relationships to disclose
Joseph Chao
No relevant relationships to disclose
Lance K. Heilbrun
No relevant relationships to disclose
Mary Jo Pilat
No relevant relationships to disclose
Daryn W. Smith
No relevant relationships to disclose
Lindsay Casetta
No relevant relationships to disclose
Scott Anthony Boerner
No relevant relationships to disclose
Patricia LoRusso
No relevant relationships to disclose